Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00262743 · ClinicalTrials.gov registry record · Phase 1
Green Tea Extract in Treating Patients With Stage 0, Stage I, or Stage II Chronic Lymphocytic Leukemia
A Phase 1 study, sponsored by Mayo Clinic.
- Completed
- Registry status
- Phase 1
- Development phase
- 73
- Enrollment target
NCT00262743: Completed Phase 1 study, sponsored by Mayo Clinic.
NCT00262743 is a Phase 1 study that has completed, run by Mayo Clinic. The registered enrollment target is 73 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00262743, a Phase 1 study, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 73 participants
- Enrollment target
Study Summary
RATIONALE: Green tea extract contains ingredients that may slow the growth of certain cancers. PURPOSE: This phase I/II trial is studying the side effects and best dose of green tea extract and to see how well it works in treating patients with stage 0, stage I, or stage II chronic lymphocytic leukemia (CLL).
Interventions
- BIOLOGICAL Polyphenon E
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 73 participants |
| Start Date | 2005-08 |
| Est. Completion | 2012-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00262743
The ClinicalTrials.gov registry entry for NCT00262743 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 73 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Polyphenon E is the first listed.
NCT00262743 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00262743 about?
NCT00262743 is a clinical study titled "Green Tea Extract in Treating Patients With Stage 0, Stage I, or Stage II Chronic Lymphocytic Leukemia". RATIONALE: Green tea extract contains ingredients that may slow the growth of certain cancers. PURPOSE: This phase I/II trial is studying the side effects and best dose of green tea extract and to see how well it works in treating patients with stage 0, stage I, or stage II chronic lymphocytic leuk...
What is the current status of trial NCT00262743?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 73 participants. The study started on 2005-08. Estimated completion is 2012-08.
What interventions are being tested in trial NCT00262743?
The interventions under investigation include: Polyphenon E (BIOLOGICAL).
Who is sponsoring clinical trial NCT00262743?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.